As Mirati Therapeutics Inc (NASDAQ:MRTX) Price Rose, Shareholder Broadfin Capital Llc Trimmed Position by $30.11 Million

May 17, 2018 - By Pearl Odom

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Corporate LogoBig Money Sentiment increased to 2.21 in 2017 Q4. It has change of 1.04, from 2017Q3’s 1.17. The ratio is positive due to MRTX positioning: 10 sold and 9 reduced. 27 funds bought stakes and 15 increased stakes. Investors holded 13.25 million in 2017Q3 but now own 17.76 million shares or 34.00% more. Wells Fargo & Mn owns 700 shs for 0% of their capital. 17,696 were reported by State Bank Of Mellon Corp. Jacobs Levy Equity has 28,500 shs for 0.01% of their capital. Citigroup Inc stated it has 41,524 shs or 0% of all its holdings. Thompson Davis And Communications Inc has 0.06% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 1,500 shs. Baker Bros Advsrs Limited Partnership has 2.55 million shs for 0.4% of their capital. Acuta Cap Prns Ltd Liability Co has invested 0.53% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Royal Retail Bank Of Canada reported 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Ameriprise holds 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 18,678 shs. Alpine Global Ltd Limited Liability Company has 0.08% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Federated Pa invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Perceptive Advisors Ltd Liability Corporation holds 0.02% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 29,091 shs. D E Shaw And holds 0.01% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 478,483 shs. 100,000 were accumulated by Artal Sa. 32,408 were reported by Goldman Sachs Gru Inc.

MRTX registered $4.97 million net activity with 0 buys and 7 selling transactions since January 11, 2018. 12,100 shs valued at $423,500 were sold by Donadio Jamie A on Friday, March 9. Christensen Jamie sold $338,476 worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) or 14,725 shs on Thursday, January 11.

The holdings In Mirati Therapeutics Inc (NASDAQ:MRTX) owned by Kevin Kotler was reduced. According to 2018Q1 SEC form the decrease is 41.01%. 1.00 million shares were sold by Broadfin Capital Llc as the company’s stock rose 63.01% while stock markets declined. The health care company at the end of 2018Q1 was priced at $44.33M. It’s down from 2.45M at the end of the previous reported quarter. Now it had 1.44M shares held by the hedge fund run by Kevin Kotler. For a total of 2.56M shares it increased its holding in Horizon Pharma Plc (NASDAQ:HZNP) by 2.26M shares in the quarter, and has risen its stake in La Jolla Pharmaceutical Co (NASDAQ:LJPC).

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

In total 5 analysts cover Mirati Therapeutics (NASDAQ:MRTX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:MRTX) has 100% bullish analysts. 5 are the (NASDAQ:MRTX)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The company rating was maintained by Citigroup on Monday, March 5. On Thursday, March 8 SunTrust maintained the shares of MRTX in report with “Buy” rating. On Thursday, December 21 the firm has “Buy” rating given by Cowen & Co. On Wednesday, April 25 the rating was maintained by H.C. Wainwright with “Buy”.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products.The firm is valued at $1.03 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.Last it reported negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: